Northland Securities Trims Esperion Therapeutics (NASDAQ:ESPR) Target Price to $5.00

Esperion Therapeutics (NASDAQ:ESPR) had its price objective trimmed by Northland Securities from $10.00 to $5.00 in a research note released on Wednesday morning, The Fly reports.

A number of other brokerages also recently weighed in on ESPR. The Goldman Sachs Group decreased their target price on shares of Esperion Therapeutics from $16.00 to $8.00 and set a sell rating for the company in a research note on Wednesday, September 22nd. Morgan Stanley downgraded shares of Esperion Therapeutics from an equal weight rating to an underweight rating and decreased their target price for the company from $17.00 to $11.00 in a research note on Thursday, October 14th. Needham & Company LLC decreased their target price on shares of Esperion Therapeutics from $20.00 to $12.00 and set a buy rating for the company in a research note on Thursday, December 9th. Cowen reduced their price target on shares of Esperion Therapeutics from $60.00 to $30.00 and set an outperform rating for the company in a research report on Tuesday, October 19th. Finally, JMP Securities reissued a buy rating and set a $90.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, September 14th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Esperion Therapeutics presently has a consensus rating of Hold and a consensus price target of $28.91.

Esperion Therapeutics stock opened at $3.93 on Wednesday. The firm has a 50-day moving average of $6.31 and a 200-day moving average of $11.05. Esperion Therapeutics has a 1-year low of $3.71 and a 1-year high of $39.49.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, November 2nd. The biopharmaceutical company reported ($2.62) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.86) by $0.24. The firm had revenue of $14.41 million for the quarter, compared to analysts’ expectations of $12.31 million. During the same quarter in the prior year, the company posted ($3.07) earnings per share. Sell-side analysts predict that Esperion Therapeutics will post -9.68 earnings per share for the current year.

Hedge funds have recently modified their holdings of the stock. Spire Wealth Management purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth $51,000. Meditor Group Ltd boosted its stake in shares of Esperion Therapeutics by 58.5% during the 4th quarter. Meditor Group Ltd now owns 4,468,835 shares of the biopharmaceutical company’s stock worth $22,344,000 after acquiring an additional 1,650,000 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Esperion Therapeutics by 9.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 92,049 shares of the biopharmaceutical company’s stock worth $1,109,000 after acquiring an additional 8,292 shares during the last quarter. Centiva Capital LP purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth $182,000. Finally, Cetera Advisor Networks LLC boosted its stake in shares of Esperion Therapeutics by 29.6% during the 3rd quarter. Cetera Advisor Networks LLC now owns 13,025 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 2,975 shares during the last quarter.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets.

Featured Story: What does the Producer Price Index (PPI) tell investors?

The Fly logo

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.